Browse result page of AntiTbPdb
The total number entries retrieved from this search are 452
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1273 | Inhibitor 3 | AK-(boroMet) | Acetylation | Free | boroMet = methionine boronic acid | Linear | 3 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 3 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1274 | Inhibitor 4 | Ala(1-naphtyl)-K-boroLeu | Free | Free | Ala(1-naphtyl) = 1-napthylalanine, boroLeu = leucine boronic acid | Linear | 3 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 12 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1275 | Inhibitor 4 | Ala(1-naphtyl)-K-boroLeu | Free | Free | Ala(1-naphtyl) = 1-napthylalanine, boroLeu = leucine boronic acid | Linear | 3 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium smegmatis | Mycobacterium smegmatis strain constitutively expressing GFP-ssrA | MIC50 = 1.5 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1276 | Inhibitor 5 | WK-(boroMet) | Addition of N-picolinoyl | Free | boroLeu = leucine boronic acid | Linear | 3 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 3 μM | In vitro | Myeloma cells (MM1.S) | NA | Slight toxic (25%) at 10 μM | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1277 | Inhibitor 6 | AK-(boroMet) | Addition of N-picolinoyl | Free | boroMet = methionine boronic acid | Linear | 3 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 3 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1278 | Inhibitor 7 | PK-(boroMet) | Addition of N-picolinoyl | Free | boroMet = methionine boronic acid | Linear | 3 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 24 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1279 | Inhibitor 8 | K-(boroMet) | Addition of N-picolinoyl | Free | boroMet = methionine boronic acid | Linear | 2 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 6 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1280 | Inhibitor 9 | K-(boroMet) | Addition of N-(3-Phenyl)propanoyl) | Free | boroMet = methionine boronic acid | Linear | 2 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 3 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1281 | Inhibitor 10 | K-(boroMet) | Addition of N-(Benzyl) | Free | boroMet = methionine boronic acid | Linear | 2 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 6 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1282 | Inhibitor 11 | K-(boroMet) | Addition of N-(2-(3,5-Difluorophenyl)acetyl) | Free | boroMet = methionine boronic acid | Linear | 2 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 6 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1283 | Inhibitor 12 | W-(boroMet) | Addition of N-(2-(3,5-Difluorophenyl)acetyl) | Free | boroMet = methionine boronic acid | Linear | 2 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 12 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1284 | Inhibitor 12 | W-(boroMet) | Addition of N-(2-(3,5-Difluorophenyl)acetyl) | Free | boroMet = methionine boronic acid | Linear | 2 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium smegmatis | Mycobacterium smegmatis strain constitutively expressing GFP-ssrA | MIC50 = 12 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1285 | Inhibitor 13 | K-(boroMet) | Addition of N-(1H-benzo(b)thiophene-7-carbonyl | Free | boroMet = methionine boronic acid | Linear | 2 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 12 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1286 | Inhibitor 14 | K-(boroMet) | Addition of N-(Phenylmetanesulfonyl) | Free | boroMet = methionine boronic acid | Linear | 2 | L | NA | Synthetic | substrate-based boronate inhibitors | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC50 = 200 μM | In vitro | Myeloma cells (MM1.S) | NA | No cytotoxicty | None | NA | NA | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. | ClpP1P2 peptidase | None | None | 2015 | 25759383 |
| antitb_1306 | D-(V13K) D1 | KWKSFLKTFKSAKKTVLHTALKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 70.7 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 421.5 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1307 | D-(V13K,A20L) D2 | KWKSFLKTFKSAKKTVLHTLLKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 83.7 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 83 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1308 | D-(V13K,A12L,A20L) D3 | KWKSFLKTFKSLKKTVLHTLLKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 109.2 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 14 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1309 | D-(V13K,A12L,A20L,A23L) D4 | KWKSFLKTFKSLKKTVLHTLLKLISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 200 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 3.5 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1310 | D-(V13K,A12L,A20L,A23L,V16K) D5 | KWKSFLKTFKSLKKTKLHTLLKLISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 35.2 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 47 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1311 | D-(V13K) D1 | KWKSFLKTFKSAKKTVLHTALKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = 57 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 7.4 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1312 | D-(V13K,A20L) D2 | KWKSFLKTFKSAKKTVLHTLLKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = 72 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 12 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1313 | D-(V13K,A12L,A20L) D3 | KWKSFLKTFKSLKKTVLHTLLKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = 100 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 0.14 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1314 | D-(V13K,A12L,A20L,A23L) D4 | KWKSFLKTFKSLKKTVLHTLLKLISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = Ie μg/mL(inactive) | In vitro | Human erythrocyte | NA | HC50 = Ie μg/mL(inactive) | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1315 | D-(V13K,A12L,A20L,A23L,V16K) D5 | KWKSFLKTFKSLKKTKLHTLLKLISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = 49 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 1.0 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1316 | L-LL37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN | Free | Free | None | Linear | 31 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = Ie μg/mL(inactive) | In vitro | Human erythrocyte | NA | HC50 = 43.5 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1317 | D-LL37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN | Free | Free | None | Linear | 31 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 200 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 125 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1318 | Peptoid 1 | H-(NLys-Nspe-Nspe)4-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 14.1μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | LD50 = 14.1μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1319 | 1-C134mer | H-Ntridec-NLys-Nspe-Nspe-NLys-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine, Ntridec = N-(tridecyl)glycine | Linear | 5 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 6.6 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | LD50 = >100 μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1320 | 14mer | H-NLys-Nspe-Nspe-NLys-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine | Linear | 4 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | NA | In vitro | Raw 264.7 and J774 mouse macrophage | NA | Non toxic | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1321 | 1-Pro9 | H-(NLys-Nspe-Nspe)2-NLys-Nspe-L-Pro-NLys-Nspe-Nspe-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 14.5 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | LD50 = 50 μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1322 | 1-11mer | H-(NLys-Nspe-Nspe)3-NLys-Nspe-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine | Linear | 11 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 14.46 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | LD50 = 50μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1323 | 1-Nssb | H-(NLys-Nssb-Nssb)4-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nssb = (S)-N-(sec-butyl)glycine | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = >100 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | Non toxic | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1324 | Peptoid 1 | H-(NLys-Nspe-Nspe)4-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 12.5-25 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | LD50 = 14.1μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1325 | 1-C134mer | H-Ntridec-NLys-Nspe-Nspe-NLys-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine, Ntridec = N-(tridecyl)glycine | Linear | 5 | L | Cationic | Synthetic | NA | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 6.3 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | LD50 = >100 μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1326 | 14mer | H-NLys-Nspe-Nspe-NLys-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine | Linear | 4 | L | Cationic | Synthetic | NA | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = >100 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | Non toxic | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1327 | 1-Pro9 | H-(NLys-Nspe-Nspe)2-NLys-Nspe-L-Pro-NLys-Nspe-Nspe-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 12.5-25 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | LD50 = 50μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1328 | 1-11mer | H-(NLys-Nspe-Nspe)3-NLys-Nspe-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nspe = (S)-N-(1-phenylethyl)glycine | Linear | 11 | L | Cationic | Synthetic | NA | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = 12.5-25 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | LD50 = 50μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1329 | 1-Nssb | H-(NLys-Nssb-Nssb)4-NH2 | Free | Amidation | Nlys = N-(4-aminobutyl)glycine, Nssb = (S)-N-(sec-butyl)glycine | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium bovis | Mycobacterium bovis BCG | MIC = >100 μM | In vitro | Raw 264.7 and J774 mouse macrophage | NA | Non toxic | NA | NA | NA | NA | NA | NA | NA | 2011 | 21464254 |
| antitb_1331 | Innate defence regulator peptide HH2 | VQLRIRVAVIRA | Free | Free | None | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | NA | Both | Human U937 promonocytic cell line | NA | None | BALB/C | 32 mg in 100 mL of saline solution (1 mg/kg) | Increase expression of MCP-1,Gro-α and TNF-α | NA | NA | NA | Antimicrobial against plasmodium aeruginosa/ S. aureus | 2012 | 23555622 |
| antitb_1332 | Innate defence regulator peptide 1002 | VQRWLIVWRIRK | Free | Free | None | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 29.3 ± 11.8 mg/mL | Both | Human U937 promonocytic cell line | NA | None | BALB/C | 32 mg in 100 mL of saline solution (1 mg/kg) | Increase expression of MCP-1,Gro-α and TNF-α | NA | NA | NA | Antimicrobial against plasmodium aeruginosa/ S. aureus | 2012 | 23555622 |
| antitb_1333 | Innate defence regulator peptide 1018 | VRLIVAVRIWRR | Free | Free | None | Linear | 12 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 16.4± 5.4 mg/mL | Both | Human U937 promonocytic cell line | NA | None | BALB/C | 32 mg in 100 mL of saline solution (1 mg/kg) | Increase expression of MCP-1,Gro-α and TNF-α | NA | NA | NA | Antimicrobial against plasmodium aeruginosa/ S. aureus | 2012 | 23555622 |
| antitb_1353 | Peptide KSl | KKVVFKVKFK | Free | Free | None | Linear | 10 | L | Cationic | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis ATCC 607 | MIC = 6.25μg/ml | In vitro | Mouse erythrocyte | NA | None | NA | NA | NA | NA | NA | NA | antifungal, antibacterial against C.albicans | 1998 | 9756752 |
| antitb_1370 | Human neutrophil peptides-1 | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | cyclic | 30 | L | Cationic | Synthetic | Human neutrophils | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37 Ra | NA | in vitro | None | NA | NA | NA | NA | NA | NA | Mycobacterial genomic DNA | NA | antibacterial against candida albicans | 2000 | 11375668 |
| antitb_1371 | Mycobacterial tuberculosis DHFR tripeptide analog | WYD | Free | Free | None | Linear | 3 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis | Kd= 1.26 × 10−7 | in silico | NA | NA | NA | NA | NA | NA | NA | mycobacteium tuberculosis DHFR | NA | 2009 | 19697148 | |
| antitb_1372 | Mycobacterial tuberculosis DHFR tripeptide analog | WYE | Free | Free | None | Linear | 3 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis | Kd= 5.02 × 10−6 | in silico | NA | NA | NA | NA | NA | NA | NA | mycobacteium tuberculosis DHFR | NA | 2009 | 19697148 | |
| antitb_1373 | Mycobacterial tuberculosis DHFR tripeptide analog | WPD | Free | Free | None | Linear | 3 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis | Kd= 9.12 × 10−9 | in silico | NA | NA | NA | NA | NA | NA | NA | mycobacteium tuberculosis DHFR | NA | 2009 | 19697148 | |
| antitb_1374 | Mycobacterial tuberculosis DHFR tripeptide analog | WPE | Free | Free | None | Linear | 3 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis | Kd= 1.02 × 10−6 | in silico | NA | NA | NA | NA | NA | NA | NA | mycobacteium tuberculosis DHFR | NA | 2009 | 19697148 | |
| antitb_1375 | Mycobacterial tuberculosis DHFR tripeptide analog | YPD | Free | Free | None | Linear | 3 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis | Kd= 4.17 × 10−8 | in silico | NA | NA | NA | NA | NA | NA | NA | mycobacteium tuberculosis DHFR | NA | 2009 | 19697148 | |
| antitb_1376 | Mycobacterial tuberculosis DHFR tripeptide analog | YPE | Free | Free | None | Linear | 3 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis | Kd= 2.75 × 10−8 | in silico | NA | NA | NA | NA | NA | NA | NA | mycobacteium tuberculosis DHFR | NA | 2009 | 19697148 | |
| antitb_1377 | Mycobacterial tuberculosis DHFR tripeptide analog | WYY | Free | Free | None | Linear | 3 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis | Kd= 1.78 × 10−9 | in silico | NA | NA | NA | NA | NA | NA | NA | mycobacteium tuberculosis DHFR | NA | 2009 | 19697148 |